IQVIA Holdings (IQV) AI Stock Analysis

• Market Cap: $24.70B
• Dividend Yield: N/A
• Average Volume (3M): 2.39M
• Price to Earnings (P/E): 20.2
• Beta (1Y): 0.88
• Revenue Growth: 2.84%
• EPS Growth: -0.16%
• Country: US
• Employees: 89,000
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 2.70
• Shares Outstanding: 173,000,000
• 10 Day Avg. Volume: 2,264,897
• 30 Day Avg. Volume: 2,385,524
• PEG Ratio: -9.30
• Price to Book (P/B): 4.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.18
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 0.41
• Enterprise Value/Gross Profit: 4.98
• Enterprise Value/Ebitda: 1.92
• 1Y Price Target: $181.14
• Price Target Upside: 22.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 15

• Rating: 76 Outperform
• Price Target: $173.00 ▲(17.39%Upside)

IQVIA Holdings presents a strong financial foundation with consistent income growth and effective cash flow management. The company faces challenges in the R&DS segment due to external uncertainties, but its solid earnings and strategic focus on technology and analytics are positives. The technical indicators point to a neutral market sentiment, and the valuation is reasonable, making IQVIA a stable investment choice with potential for growth.

Positive Factors

Capital Deployment Strategy

The recent $2 billion senior notes offering will support share buybacks and M&A, with management leaning towards share repurchase due to the stock's low valuation.

Competitive Position

IQVIA continues to execute and demonstrates a strong competitive position despite a challenging macro environment.

TAS Segment Performance

The TAS segment is experiencing a resumption of growth with management confident in its continued performance, supported by over 100 FDA approvals.

Negative Factors

Policy Changes Impact

The announced policy changes by the new US administration have led to uncertainty and delays in decision-making by Pharma and Biotech customers.

Policy Uncertainty

Policy uncertainty is slowing decision-making in the R&DS segment, with elongated decision cycles and impacted study starts.

R&DS Revenue Growth

Despite satisfactory RFP flows, R&DS bookings still lag below targets, contributing to depressed revenue growth in the segment.

IQVIA Holdings Business Overview & Revenue Model

Company Description

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

How the Company Makes Money

IQVIA Holdings generates revenue through a diversified model primarily comprising three key streams: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides data analytics, consulting, and technology solutions that help clients optimize their commercial operations and research activities. Research & Development Solutions offer contract research services that encompass clinical trial management, regulatory affairs, and laboratory services, aiding pharmaceutical companies in the drug development process. The Contract Sales & Medical Solutions segment involves sales force management and healthcare provider education services, assisting clients in effectively engaging with healthcare professionals. Additionally, IQVIA benefits from strategic partnerships with pharmaceutical companies and healthcare providers, which further bolster its revenue streams.

IQVIA Holdings Financial Statement Overview

Summary

IQVIA Holdings demonstrates robust financial performance with consistent revenue growth, effective cost management, and strong cash flow generation. The company's financial metrics are solid, but attention to managing total liabilities is important for sustained financial health.

Income Statement

IQVIA Holdings has demonstrated a consistent revenue growth trajectory over the past years, with a revenue increase from $13.87 billion in 2021 to $15.49 billion in TTM 2025, reflecting steady demand in its sector. The gross profit margin remains robust, showcasing effective cost management. The net profit margin has also shown resilience, indicating strong bottom-line performance. EBIT and EBITDA margins highlight operational efficiency and a solid earnings base.

Balance Sheet

The company maintains a healthy equity position with an equity ratio of approximately 21.87% as of TTM 2025, reflecting a stable financial structure. The debt-to-equity ratio has improved notably, indicating effective leverage management. Return on Equity (ROE) is strong, underscoring efficient use of shareholder equity to generate profits. However, attention to managing total liabilities is advised to maintain financial stability.

Cash Flow

IQVIA Holdings exhibits strong cash flow generation with a consistent increase in operating cash flows, reflecting the company's capacity to generate cash from core operations. The free cash flow has grown significantly, supporting the company's ability to fund growth opportunities and return value to shareholders. The cash flow to net income ratios illustrates efficient conversion of earnings into cash flows.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
15.50B	15.40B	14.98B	14.41B	13.87B	11.36B
	Gross Profit
5.11B	5.38B	5.24B	5.03B	4.64B	3.86B
	EBIT
2.22B	2.20B	1.98B	1.80B	1.39B	731.00M
	EBITDA
3.38B	3.46B	3.30B	2.89B	2.75B	2.06B
	Net Income Common Stockholders
1.33B	1.37B	1.36B	1.09B	966.00M	279.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.74B	1.84B	1.50B	1.31B	1.48B	1.90B
	Total Assets
27.32B	26.90B	26.68B	25.34B	24.69B	24.56B
	Total Debt
1.40B	14.16B	14.23B	13.01B	12.44B	12.90B
	Net Debt
-341.00M	12.45B	12.86B	11.79B	11.07B	11.09B
	Total Liabilities
21.34B	20.83B	20.57B	19.57B	18.65B	18.28B
	Stockholders Equity
5.98B	6.07B	6.11B	5.76B	6.04B	6.00B
Cash Flow		Free Cash Flow
2.31B	2.11B	1.50B	1.59B	2.30B	1.34B
	Operating Cash Flow
2.76B	2.72B	2.15B	2.26B	2.94B	1.96B
	Investing Cash Flow
-1.44B	-1.44B	-1.60B	-2.01B	-2.10B	-796.00M
	Financing Cash Flow
-1.03B	-878.00M	-382.00M	-329.00M	-1.24B	-217.00M

IQVIA Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 147.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IQV, the sentiment is Neutral. The current price of 147.37 is above the 20-day moving average (MA) of 143.64, below the 50-day MA of 150.75, and below the 200-day MA of 196.23, indicating a neutral trend. The MACD of -2.39 indicates Negative momentum. The RSI at 51.92 is Neutral, neither overbought nor oversold. The STOCH value of 85.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IQV.

IQVIA Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DGX	79 Outperform	$19.38B	21.94	13.35%	1.75%	9.38%	6.43%
IQV	76 Outperform	$24.70B	20.16	21.65%	―	2.84%	-0.16%
DHR	72 Outperform	$137.45B	37.23	7.22%	0.59%	-9.19%	-12.75%
RVTY	65 Neutral	$10.73B	35.99	3.82%	0.30%	1.62%	78.53%
ICLR	64 Neutral	$10.80B	15.19	8.01%	―	-0.48%	11.47%
MEDP	63 Neutral	$8.99B	22.41	65.82%	―	9.87%	32.81%
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%

IQVIA Holdings Corporate Events

IQVIA Holdings Issues $2 Billion in Senior Notes

On June 4, 2025, IQVIA Inc., a subsidiary of IQVIA Holdings Inc., successfully issued and sold $2 billion in 6.250% senior notes due 2032. The proceeds from this offering will be used to repay existing borrowings under the company’s revolving credit facility and cover related fees and expenses, with any remaining funds allocated for general corporate purposes. This financial maneuver is expected to impact the company’s operations by optimizing its debt structure and potentially enhancing its market positioning.

The most recent analyst rating on (IQV) stock is a Hold with a $160.00 price target. To see the full list of analyst forecasts on IQVIA Holdings stock, see the IQV Stock Forecast page.

IQVIA Holdings Announces $2 Billion Senior Notes Offering

On June 2, 2025, IQVIA Holdings Inc. announced that its subsidiary, IQVIA Inc., plans to raise $2 billion through a senior notes offering due in 2032. The proceeds will be used to repay existing borrowings and cover related fees, with any excess allocated for general corporate purposes. This move is expected to impact the company’s financial structure and market positioning, subject to customary closing conditions.

The most recent analyst rating on (IQV) stock is a Hold with a $242.00 price target. To see the full list of analyst forecasts on IQVIA Holdings stock, see the IQV Stock Forecast page.